PwC pre­dicts 'flur­ry' of $5B to $15B biotech deals in 2023

PwC’s phar­ma in­dus­try trends analy­sis is here — and the au­dit com­pa­ny is pre­dict­ing sev­er­al neg­a­tives amid mod­est ex­pec­ta­tions for M&A, cov­er­ing every­thing from high in­fla­tion and ris­ing cap­i­tal costs to in­creased FTC scruti­ny, just to name a few.

The re­port rec­om­mends lead­ers fo­cus on four key ar­eas: dig­i­tiz­ing the val­ue chain, “get­ting fit for growth” by re­think­ing where they al­lo­cate funds, find­ing ways to adapt to pres­sure on drug pric­ing and “win­ning” in M&A.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER